• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.

    As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Stockholders Meeting in January 2024. With the addition of Chattopadhyay, Ashland temporarily increases the size of the Board to 11 members until the next Annual Stockholders Meeting in January 2024.

    Chattopadhyay is a broadly experienced global executive who brings strong industry leadership in manufacturing, distribution, supply chain, and more. He has led complex operations that span 22 countries including cutting-edge manufacturing technology while successfully navigating the ever-changing, globally complex, and heavily regulated industry of biopharmaceuticals.

    "I am pleased to welcome Sanat as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy and increase our focus and scale in pharmaceuticals, personal care and coatings, I am confident Sanat will provide important perspectives for our team. And once again, I want to thank Jay and Brendan for their dedicated service to the Board."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    Seth A. MrozekCarolmarie C. Brown
    +1 (302) 594-5010+1 (302) 995-3158
    [email protected][email protected]

    Attachment

    • Ashland_announces_new_board_member_20231114


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ASH
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Ashland Inc.
    $ASH
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Ashland Inc.
    $ASH
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    Ashland Inc.
    $ASH
    3/5/2025Buy → Neutral
    Seaport Research Partners
    Merck & Company Inc.
    $MRK
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    Merck & Company Inc.
    $MRK
    1/8/2025$110.00Buy → Hold
    Truist
    More analyst ratings

    $ASH
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and GM, Life Sciences Assis Alessandra Faccin exercised 3,123 shares at a strike of $51.26 and covered exercise/tax liability with 1,327 shares, increasing direct ownership by 57% to 4,946 units (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      7/28/25 4:30:42 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by SVP, CFO & PFO Whitaker William

      4 - ASHLAND INC. (0001674862) (Issuer)

      7/22/25 4:30:07 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Chattopadhyay Sanat

      4 - ASHLAND INC. (0001674862) (Issuer)

      7/2/25 4:30:04 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck Announces Fourth-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

      7/22/25 11:53:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Whitaker named senior vice president and chief financial officer, Ashland

      WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that the board of directors has named William C. Whitaker, senior vice president and chief financial officer, Ashland, effective July 18, 2025. Whitaker has been serving as the company's interim chief financial officer. Whitaker joined Ashland in 2015. He has held several positions of increasing responsibility in corporate development, treasury, financial planning and analysis (FP&A) and investor relations. Prior to Ashland, Whitaker held roles outside of the company within private equity and transaction advisory services. He earned a Bachelor's degree in Finance from Ohio State University and h

      7/21/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹

      Approval is based on the results from phase III KEYNOTE-A18/ENGOT-cx11/GOG-30472 KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients

      7/21/25 11:00:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASH
    $MRK
    SEC Filings

    See more
    • Amendment: Ashland Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - ASHLAND INC. (0001674862) (Filer)

      7/28/25 5:29:28 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland Inc. filed SEC Form 8-K: Leadership Update

      8-K - ASHLAND INC. (0001674862) (Filer)

      7/21/25 5:02:09 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Ashland Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - ASHLAND INC. (0001674862) (Filer)

      7/14/25 5:02:47 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:04:52 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

      4 - ASHLAND INC. (0001674862) (Issuer)

      2/3/25 4:30:05 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Merck downgraded by Citigroup with a new price target

      Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

      5/14/25 8:57:17 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ashland downgraded by Wells Fargo

      Wells Fargo downgraded Ashland from Overweight to Equal Weight

      5/1/25 3:02:01 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Cantor Fitzgerald initiated coverage on Merck with a new price target

      Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

      4/22/25 8:01:38 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASH
    $MRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Ashland announces executive leadership changes

      WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

      5/5/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

      Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

      9/3/24 7:00:00 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary

    $ASH
    $MRK
    Financials

    Live finance-specific insights

    See more
    • Merck Announces Fourth-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

      7/22/25 11:53:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ashland sets date for third-quarter fiscal 2025 earnings release and conference call webcast

      WILMINGTON, Del., July 16, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its third-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, July 29, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Wednesday, July 30. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, interim chief financial officerDago C

      7/16/25 5:00:00 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

      7/1/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASH
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ashland Inc.

      SC 13G - ASHLAND INC. (0001674862) (Subject)

      11/12/24 11:54:03 AM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Ashland Inc.

      SC 13G/A - ASHLAND INC. (0001674862) (Subject)

      7/10/24 1:14:41 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

      SC 13D/A - ASHLAND INC. (0001674862) (Subject)

      4/25/24 4:15:12 PM ET
      $ASH
      Specialty Chemicals
      Consumer Discretionary